A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis
Status: Recruiting
Location: See all (45) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 17
Healthy Volunteers: f
View:
• Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
• Participants must have at least three joints that are affected by arthritis.
• Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
Locations
United States
California
Local Institution - 0038
WITHDRAWN
Lancaster
Illinois
Local Institution - 0020
WITHDRAWN
Chicago
Indiana
Local Institution - 0023
WITHDRAWN
Indianapolis
New York
Local Institution - 0059
WITHDRAWN
North New Hyde Park
Ohio
Local Institution - 0065
WITHDRAWN
Cincinnati
Local Institution - 0066
WITHDRAWN
Cleveland
Texas
Local Institution - 0036
WITHDRAWN
Austin
Other Locations
Brazil
Santa Casa de Misericordia de Belo Horizonte
RECRUITING
Belo Horizonte
Local Institution - 0032
WITHDRAWN
Cuiabá
Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância
RECRUITING
Curitiba
Local Institution - 0013
WITHDRAWN
Curitiba
Centro de Oncologia Leonardo Da Vinci - ATO Terapias
RECRUITING
Fortaleza
LMK Serviços Médicos S/S
RECRUITING
Porto Alegre
Local Institution - 0033
WITHDRAWN
Porto Alegre
Hospital Das Clinicas Ufpe
RECRUITING
Recife
Local Institution - 0027
NOT_YET_RECRUITING
Rio De Janeiro
Local Institution - 0010
WITHDRAWN
São Paulo
Santa Casa Instituto de Pesquisa
RECRUITING
São Paulo
PSEG- Pesquisa Clínica
RECRUITING
Vila Clementino
Bulgaria
University Multiprofile Hospital for Active Treatment Sveti Georgi EAD
RECRUITING
Plovdiv
Local Institution - 0062
WITHDRAWN
Sofia
Local Institution - 0069
NOT_YET_RECRUITING
Sofia
China
Local Institution - 0049
NOT_YET_RECRUITING
Beijing
Local Institution - 0074
NOT_YET_RECRUITING
Beijing
The First Hospital of Jilin University
RECRUITING
Changchun
The Children's Hospital of Chongqing Medical University
RECRUITING
Chongqing
Guangzhou Women and Children's Medical Center
RECRUITING
Guangzhou
The Children's Hospital of Zhejiang University School of Medicine
RECRUITING
Hangzhou
Childrens Hospital of Nanjing Medical University
RECRUITING
Nanjing
Children's Hospital of Fudan University
RECRUITING
Shanghai
Germany
Kinderklinik des Uni-Klinikums Erlangen
RECRUITING
Erlangen
Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari
RECRUITING
Hamburg
Italy
Azienda Ospedaliera Universitaria Meyer IRCCS
RECRUITING
Florence
University of Naples Federico II
RECRUITING
Naples
Puerto Rico
Local Institution - 0017
WITHDRAWN
San Juan
Romania
Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca
RECRUITING
Cluj-napoca
Local Institution - 0048
WITHDRAWN
Iași
Sc Medaudio-Optica Srl
RECRUITING
Râmnicu Vâlcea
Spain
Hospital Universitari Vall d'Hebron
RECRUITING
Barcelona
Hospital Universitario Ramón y Cajal
RECRUITING
Madrid
Hospital Universitari i Politecnic La Fe
RECRUITING
Valencia
Turkey
Local Institution - 0044
NOT_YET_RECRUITING
Ankara
Local Institution - 0061
NOT_YET_RECRUITING
Ankara
Umraniye Training and Research Hospital
RECRUITING
Istanbul
Istanbul Universitesi Cerrahpasa
RECRUITING
Istanbul- Fatih
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2025-03-13
Estimated Completion Date: 2031-03-04
Participants
Target number of participants: 60
Treatments
Experimental: Arm A
Placebo_comparator: Arm B
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb